News Home

Where Does Wall Street Think HTG Molecular Diagnostics (HTGM) Stock Will Go?

Monday, November 23, 2020 11:12 AM | InvestorsObserver Analysts
Where Does Wall Street Think HTG Molecular Diagnostics (HTGM) Stock Will Go?

InvestorsObserver is giving HTG Molecular Diagnostics (HTGM) an Analyst Rating Rank of 67, meaning HTGM is ranked higher by analysts than 67% of stocks. The average projection by analysts for HTGM is $1.125 over the next 12 months and analyst’s classify the stock as a Strong Buy

Overall Score - 4.6
Wall Street analysts are rating HTGM a Strong Buy today. Find out what this means to you and get the rest of the rankings on HTGM!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.

InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With HTG Molecular Diagnostics Stock Today?

HTG Molecular Diagnostics (HTGM) stock has fallen -2.42% while the S&P 500 is up 0.52% as of 11:08 AM on Monday, Nov 23. HTGM is lower by -$0.10 from the previous closing price of $4.27 on volume of 316,646 shares. Over the past year the S&P 500 has gained 14.11% while HTGM is lower by -56.56%. HTGM lost -$0.32 per share the over the last 12 months.

Click Here to get the full report on HTG Molecular Diagnostics (HTGM) Stock.

You May Also Like